VRDN — Viridian Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $1.10bn
- $464.23m
- $0.30m
Annual cashflow statement for Viridian Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -111 | -79.4 | -130 | -238 | -270 |
| Depreciation | |||||
| Non-Cash Items | 76.3 | 23 | 19.8 | 62.5 | 27.5 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 4.43 | 1.72 | 16 | -9.43 | 9.6 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -29.8 | -54.6 | -93.8 | -184 | -232 |
| Capital Expenditures | -0.042 | -0.338 | -0.797 | -0.898 | -0.511 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -50.4 | -74 | -114 | -93.4 | -228 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -50.5 | -74.3 | -115 | -94.3 | -229 |
| Financing Cash Flow Items | -1.35 | -6.95 | -18.9 | -7.15 | -26.3 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 101 | 125 | 322 | 226 | 458 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 21.1 | -3.6 | 113 | -52.8 | -3.23 |